Lung Cancer | Tumor

CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.

Novel Drug-Tecentriq Combo to Be Studied in Non-Small Cell Lung Cancer

June 17th 2022

A phase 2a trial is kicking off to study frontline GB1211 with the immunotherapy agent Tecentriq in patients with advanced or metastatic non-small cell lung cancer.

A Paradigm Shift in the Treatment of Early-Stage Lung Cancer May Be Leading to More Cures

June 16th 2022

Instead of waiting until the disease has progressed, researchers have begun analyzing the effects of using immunotherapy before or after surgery in patients with early-stage lung cancer. The results, according to experts, may be transformative for patients.

Durable Responses Continue with Keytruda Plus Chemoradiation in Previously Untreated Non-Small Cell Lung Cancer

June 8th 2022

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

Exkivity Delivers Minimal Benefit to Patients with Non-Small Cell Lung Cancer and Brain Metastases

June 8th 2022

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer

June 6th 2022

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer

June 6th 2022

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset

June 4th 2022

Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

Unmet Needs in the Management of EGFR Exon 20–Positive NSCLC

May 27th 2022

Before closing out their discussion on treatment for EGFR Exon 20–Positive NSCLC, experts discuss prominent unmet needs in this setting.

Telehealth Use for Cancer Care Surged During COVID-19, But Inequalities Remain

May 27th 2022

An analysis of more than 25,000 patients with one of the more than 20 common cancers identified that even though telehealth use for cancer care increased during the COVID-19 pandemic, certain people were less likely to benefit from the easy access to care.

Investigators Launch Study to Review Novel Cancer Vaccine in Patients With Advanced Solid Tumors

May 26th 2022

A clinical trial just launched to study Vaxinia — a novel cancer vaccine — in patients with previously treated advanced solid tumors.

Enrolling in Clinical Trials for EGFR Exon 20–Positive NSCLC

May 20th 2022

A shared discussion on the importance of enrolling in clinical trials for EGFR exon 20–positive NSCLC and improving access to novel therapy for patients.

Improving Quality of Life While Receiving Treatment for NSCLC

May 20th 2022

A focused conversation on how a patient can maintain and improve quality of life while receiving therapy for non–small cell lung cancer.

Cancer Trial Hopes to Find New Patient Populations That Will Respond to Already-Approved Drugs

May 19th 2022

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Support for Patients Undergoing Treatment for NSCLC

May 13th 2022

Comprehensive discussion on support for patients receiving therapy for NSCLC, ranging from care team members to education materials to support groups.

How to Decide on Novel Therapy for EGFR Exon 20–Positive NSCLC

May 13th 2022

Looking at available novel therapy for EGFR exon 20 insertion–positive NSCLC, experts consider how patients can play a part in identifying their best treatment option.

Educating Patients About Cancer Should Not Be a ‘One-Size-Fits-All’ Approach, Says Expert

May 11th 2022

When it comes to learning about their disease, patients with cancer can have different preferences, from wanting to discuss treatments with their providers or read handouts, while others may not want to know much at all.

Use of Amivantamab in patients with EGFR Exon 20–Positive Non–Small Cell Lung Cancer

May 6th 2022

An expert in the lung cancer and a representative from lung cancer advocacy group talk about the use of amivantamab, a novel therapy approved for treating EGFR exon 20 insertion–positive disease.

Access to Novel Therapy for EGFR Exon 20–Positive NSCLC

May 6th 2022

A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC.

Driving Lung Cancer Research With Compassion

April 30th 2022

Livia Szeto, B.S.N., RN, OCN, has "unparalleled" patient relationships and research skills, allowing her to provide excellent care.

The Importance of Molecular Profiling and Patient Education in NSCLC

April 29th 2022

Shared insight on how molecular profiling can impact the management of EGFR exon 20 insertion–positive NSCLC and how patient advocacy groups can help patients to interpret test results.

Overview of EGFR Exon 20 and Molecular Testing in NSCLC

April 29th 2022

Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling.

Imfinzi May Be Better in a Combination for Advanced Lung Cancer

April 27th 2022

Imfinzi alone is the standard of care in this patient population, however two combinations may have better outcomes.

Patient Receives Treatment With Novel Drug in First-in-Human Trial Assessing its Safety and Efficacy in Brain and Lung Cancer

April 25th 2022

The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.

A Step Forward in Treating KRAS G12-Mutated Lung Cancer

April 18th 2022

Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.

Treatment Advancements in Lung Cancer Lead to ‘Tremendous Growth’

April 16th 2022

Recent advancements surrounding the development of biomarker- targeted therapies have revolutionized the treatment of lung cancer.

What Patients With Lung Cancer Don’t Know May Be Critically Important

April 14th 2022

Patients who are part of an advocacy group may be better equipped to understand biomarker testing during a lung cancer diagnosis and feel more empowered.

Targeted Therapy Advances in Lung Cancer Space Over Past 2 Decades 'Simply Remarkable'

April 14th 2022

Over the past 20 years, advancements in the lung cancer space have led to a drastic paradigm shift in how patients are now treated, ultimately leading to substantial improvements in survival and patient quality of life.

FDA’s Approval of Opdivo-Chemo Regimen Spurs Another Thought-Provoking Treatment Option in Lung Cancer

April 13th 2022

The FDA’s recent approval of Opdivo plus chemotherapy may be beneficial for some patients with non-small cell lung cancer, further highlighting the need for multidisciplinary care.

A New Path Emerges in Lung Cancer Treatment

April 13th 2022

Anti-TIGIT immunotherapy drugs may improve quality of life and survival, while being well tolerated by patients.

KRAS G12C Lung Cancer: New Therapies Treat the 'Undruggable'

April 12th 2022

The KRAS G12C gene mutation in non-small cell lung cancer has been deemed “undruggable,” but recent effective therapies have successfully targeted this mutation, leading to shrinking of tumors and longer survival.